Home » Newsletters » BioWorld Science

BioWorld Science

March 1, 2002

View Archived Issues

U.S. launch of new injectable carbapenem announced by Merck

Bextra now available for prescription in the U.S.

Evidence of antipsoriatic activity obtained in phase II trial of topical alicaforsen

Newly introduced Elidel cream associated with reduced disease flares and corticosteroid use

Xanelim pivotal results discussed at the AAD meeting; BLA may be filed this summer

Novel class of analgesics --VR1 blockers-- discovered by Spanish researchers

IL-6 exerts central antiobesity effects in rodents

Cubist and Novartis extend antiinfective drug discovery collaboration

Caprion and McGill University to collaborate on proteomics research

FlowGuard approved in U.S.

NDA filed for acamprosate for the treatment of alcohol dependency

Initiation of phase II trial of MVA-HPV-IL-2 in cervical intraepithelial neoplasia

FDA approves new indication for Plavix in acute coronary syndrome

Schering initiates phase III BENEFIT study of Betaferon/Betaseron

MS-818 accelerates early muscle regeneration and enhances recovery postsurgery

ImClone and partners discuss resubmission of Erbitux BLA with FDA

Access acquires targeted therapeutic division of Biotech Australia

Once- or twice-yearly i.v. zoledronic acid effective in postmenopausal osteoporosis

Tissue-specific selfinactivating gene therapy described by UAB Research Foundation

Ranbaxy designs compounds effective against Gram-positive and anaerobic bacteria

Compounds with high affinity for the alpha5 subunit of GABA-A receptors

Phosphate esters of peptidomimetic compounds for treatment of HIV infection

American Cyanamid prepares new inhibitors of TACE and other MMPs

Inhibitors of factor Xa with utility in thrombosis associated with cardiovascular disorders

DuPont discloses compounds for the treatment of anxiety and depression

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...